GlassScriptPhysician profile
Sean Michael Heffelfinger
NPI 1265483341
$961.71
in general payments reported to CMS, 2019-2025
22 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $70.43 · 2021: $76.85 · 2022: $52.61 · 2023: $243 · 2024: $110 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $156.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $141.53 | 2019-2025 | Lokelma, Breztri, Airsupra |
| Abbvie INC. | $76.06 | 2021-2025 | |
| Amarin Pharma, INC. | $73.48 | 2019-2023 | |
| Amgen INC. | $68.80 | 2019-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $56.85 | 2025 | |
| Janssen Pharmaceuticals, INC | $49.31 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $34.32 | 2023-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $33.27 | 2023-2025 | Arexvy, Shingrix |
| Pfizer INC. | $30.81 | 2025 | |
| Exact Sciences Corporation | $30.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $29.51 | 2023 | Wellbutrin, Aplenzin |
| Phathom Pharmaceuticals, INC. | $24.90 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $21.61 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $20.91 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $18.75 | 2024 | |
| Almatica Pharma LLC | $17.56 | 2023 | Gralise, Loreev Xr |
| Allergan, INC. | $17.24 | 2019 | |
| Astellas Pharma US INC | $16.48 | 2019 | |
| Novo Nordisk INC | $16.10 | 2025 | |
| Philips North America LLC | $13.84 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Heffelfinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.